Drug Search Results
More Filters [+]

Izokibep

Alternative Names: izokibep, aby-035, aby035, aby 035, afo2, aby-035/afo2, IMG020, IMG-020
Latest Update: 2024-09-30
Latest Update Note: Clinical Trial Update

Product Description

Izokibep is a unique antibody mimetic and potent interleukin-17A (IL-17A) inhibitor designed to overcome the limitations of existing monoclonal antibodies.

Mechanisms of Action: IL17A Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: ACELYRIN
Company Location:
Company CEO:
Additonal Commercial Interests: Affibody

Clinical Description

Map of Global Clinical Trials for Izokibep

Countries in Clinic: Austria, Bulgaria, Canada, China, Czech Republic, France, Germany, Hungary, Italy, Japan, Poland, Spain, United States, Unknown Location

Active Clinical Trial Count: 12

Highest Development Phases

Phase 3: Arthritis, Psoriatic|Hidradenitis Suppurativa

Phase 2: Panuveitis|Spondylitis, Ankylosing|Uveitis|Uveitis, Intermediate|Uveitis, Posterior

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

jRCT2031230501

P3

Not yet recruiting

Hidradenitis Suppurativa

2025-12-31

22107

P3

Unknown Status

Hidradenitis Suppurativa

2025-12-17

NCT05384249

P2

Active, not recruiting

Panuveitis

2025-08-07

21103

P2

Unknown Status

Uveitis, Posterior|Uveitis, Intermediate

2025-06-19

Recent News Events